Work

Abstract CT219: A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox Trial

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct219

Authors: Michael B. Sawyer, Barry A. Badeau, Allison J. Gardner, Meghan Joly, William Riedl, LuAnn Sabounjian, Jillian L. Seiler, Brad Studnitzer, Emma Zhang, Russell Potterfield, Daniel L. Marks

Institution: University of Alberta

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154716966

Cites:

Cited by:

Related to: